AEGEAN
Regimen
- Experimental
- neoadj durva+chemo → surgery → adjuvant durva
- Control
- neoadj chemo → placebo
Population
Resectable stage II-IIIB NSCLC
Key finding
EFS HR 0.68 (0.53-0.88); pCR 17.2% vs 4.3%; durva perioperative benefit
Source: PMID 37870974
Timeline
- Enrollment start: 2018-12-06 📎
Guideline citations
- CSCO NSCLC 2025 ⚠️ OCR source